Cargando…

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylact...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, R I, van Beurden, M, Lubsen, M A C, Rookus, M A, Mooij, T M, van de Vijver, M J, van't Veer, L J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409718/
https://www.ncbi.nlm.nih.gov/pubmed/15083174
http://dx.doi.org/10.1038/sj.bjc.6601692
_version_ 1782155842313781248
author Olivier, R I
van Beurden, M
Lubsen, M A C
Rookus, M A
Mooij, T M
van de Vijver, M J
van't Veer, L J
author_facet Olivier, R I
van Beurden, M
Lubsen, M A C
Rookus, M A
Mooij, T M
van de Vijver, M J
van't Veer, L J
author_sort Olivier, R I
collection PubMed
description A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers.
format Text
id pubmed-2409718
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24097182009-09-10 Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up Olivier, R I van Beurden, M Lubsen, M A C Rookus, M A Mooij, T M van de Vijver, M J van't Veer, L J Br J Cancer Clinical A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers. Nature Publishing Group 2004-04-19 2004-03-16 /pmc/articles/PMC2409718/ /pubmed/15083174 http://dx.doi.org/10.1038/sj.bjc.6601692 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Olivier, R I
van Beurden, M
Lubsen, M A C
Rookus, M A
Mooij, T M
van de Vijver, M J
van't Veer, L J
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title_full Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title_fullStr Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title_full_unstemmed Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title_short Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
title_sort clinical outcome of prophylactic oophorectomy in brca1/brca2 mutation carriers and events during follow-up
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409718/
https://www.ncbi.nlm.nih.gov/pubmed/15083174
http://dx.doi.org/10.1038/sj.bjc.6601692
work_keys_str_mv AT olivierri clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT vanbeurdenm clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT lubsenmac clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT rookusma clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT mooijtm clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT vandevijvermj clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup
AT vantveerlj clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup